Newly Cleared Genetic Test Will Allow Patient Targeting For Pfizer’s Camptosar
This article was originally published in The Pink Sheet Daily
Executive Summary
Third Wave’s Invader test will identify patients with two copies of the variant allele UGT1A1, which increases the risk of developing neutropenia while on irinotecan.
You may also be interested in...
Camptosar Reduced Starting Dose Recommended In Patients With Genetic Marker
Patients with the deficiency of a metabolizing enzyme have an increased risk of neutropenia, revised labeling for Pfizer’s oncologic says. Patients with the deficiency should start at a lower dose, though the appropriate starting dose is not known, FDA says.
Tarceva Pancreatic Cancer Indication Turned Down In The EU
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.
Teva To Investigate High-Dose Copaxone
A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.